X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Aventis Pharma: Strategic focus - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Mar 20, 2003

    Aventis Pharma: Strategic focus

    Aventis Pharma Limited, one of the leading pharmaceutical companies in India, recently announced FY03 results. We take a detailed look at the company's performance.

    (Rs m) 4QFY02 4QFY03 Change FY02 FY03 Change
    Net Sales 1,513 1,576 4.2% 5,462 6,157 12.7%
    Other Income 40 26 -35.0% 127 98 -22.8%
    Total expenditure 1,226 1,310 6.9% 4,476 5,185 15.8%
    Operating Profit (EBDIT) 287 266 -7.3% 986 972 -1.4%
    Operating Profit Margin (%) 19.0% 16.9%   18.1% 15.8%  
    Interest (net) 0 0 - 15 4 -73.3%
    Depreciation 38 38 0.0% 151 150 -0.7%
    Profit before Tax 289 254 -12.1% 947 916 -3.3%
    Extraordinary items -39 -5 - -8 -9 -
    Tax 60 81 35.0% 273 296 8.4%
    Profit after Tax/(Loss) 190 168 -11.6% 666 611 -8.3%
    Effective tax rate (%) 20.8% 31.9%   28.8% 32.3%  
    Net profit margin (%) 12.6% 10.7%   12.2% 9.9%  
    No. of Shares (eoy) (m) 23.0 23.0   23.0 23.0  
    Earnings per share* 33.0 29.2   29.0 26.6  
    Current P/e ratio   8.8     9.7  
    *(annualised)            

    Aventis reported 4% topline growth in the December quarter, led by an encouraging 15% growth in the domestic pharma business. Rhone Poulenc added 1.4% to this domestic sale spurt. Exports were down 22% during the quarter. In the full year 2002, domestic sales were up nearly 9% and exports displayed a growth of 27% (led by exports to Russia and CIS countries). Overall, Aventis finished FY03 with nearly 13% topline growth. Aventis domestic sales performance was in line with the industry sales trend. However, the company had discontinued certain non-profitable products accounting for 4% of 2001 sales. In that sense, Aventis did well in the domestic markets.

    Over the last few years, Aventis has restructured its product folio and is currently focusing on 30 brands for the domestic market. Out of the these, 12 brands fall under the purview of the DPCO, representing 38% of FY03 domestic sales. The contribution from products under DPCO has come down to these levels from over 50% just a couple of years ago.

    Sales: Vital stats...
    (Rs m) 4QFY02 4QFY03 Change FY02 FY03 Change
    Domestic sales 1,070 1,230 15.0% 4,246 4,611 8.6%
    Exports 443 346 -21.9% 1,216 1,546 27.1%
    Total Sales 1,513 1,576 4.2% 5,462 6,157 12.7%

    The top 10 brands accounted for 72% of domestic sales in FY03 and grew by 16% YoY. Growth in strategic brands such as Clexane (44% growth), Amaryl (anti diabetes - 41% growth), Targocid (Anti-infective - 34%), Cardace (Cardiovascular - 32%) and Allegra (anti-histamine - 15%) peppered the domestic performance of the company. Growth for anti-rabies vaccine 'Rabipur' was over 13% YoY. It must be noted that the company has almost 80% market share in the anti-rabies segment. However, going forward the entry of Cadila in this segment may take away some share from Aventis in this category.

    Operating margins of the company declined significantly. This was largely as a result of an 18% increase in raw material costs brought about by imposition of customs duties on Clexane and Cefrom as well as rupee depreciation. This and a 23% dip in the company's other income resulted in Aventis reporting an 8% fall at net profit level.

    Cost break-up
    (Rs m) 4QFY02 4QFY03 Change FY02 FY03 Change
    Raw material 791 907 14.7% 2,830 3,332 17.7%
    Staff cost 122 127 4.1% 464 510 9.9%
    Other expenditure 313 276 -11.8% 1,182 1,343 13.6%
    Total 1,226 1,310 6.9% 4,476 5,185 15.8%

    At the current price of Rs 257, the stock trades at almost 10x FY03 earnings. On the back of the support extended by the parent, Aventis has transformed itself from a company catering mainly to the anti-infectives and pain management segments to a company with a strong and focused portfolio of products for the chronic and critical-care therapeutic segments. The strategic brands continue to show healthy growth rates and this is expected to offset the impact of the laggards in its folio.

     

     

    Equitymaster requests your view! Post a comment on "Aventis Pharma: Strategic focus". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    SANOFI INDIA SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK SANOFI INDIA

    • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    SANOFI INDIA - CADILA HEALTHCARE COMPARISON

    Compare Company With Charts

    COMPARE SANOFI INDIA WITH

    MARKET STATS